ASTH

Astrana Health Inc

Add to Watchlist

Advanced Chart

28.080

+6.62(30.848%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

29.760

Open

24.000

VWAP

27.75

Vol

1.81M

Mkt Cap

1.40B

Low

23.850

Amount

50.21M

EV/EBITDA(TTM)

12.56

Total Shares

49.93M

1.25B

EV/OCF(TTM)

9.54

P/S(TTM)

0.56

Astrana Health, Inc. is a physician-centric, artificial intelligence (AI)-powered healthcare company focused on delivering patient-centered care. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's segments include Care Partners, Care Delivery, and Care Enablement. Its Care Partners segment is focused on building and managing provider networks by partnering with, empowering, and investing in provider partners aligned on a shared vision for coordinated care delivery. Its Care Delivery organization includes primary care, multi-specialty care, and ancillary care services. Its Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information. It supports more than 20,000 providers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

979.67M

+57.91%

975.25M

+46.61%

946.09M

+97.63%

Estimates Revision

The market is revising Upward the revenue expectations for Astrana Health, Inc. (ASTH) for FY2025, with the revenue forecasts being adjusted by 21.49% over the past three months. During the same period, the stock price has changed by -1.61%.

Revenue Estimates for FY2025

Revise Upward

+21.49%

In Past 3 Month

Stock Price

Go Down

-1.61%

In Past 3 Month

9 Analyst Rating

70.44% Upside

Wall Street analysts forecast ASTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASTH is 47.86 USD with a low forecast of 36.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

70.44% Upside

Current: 28.080

Low

36.00

Averages

47.86

High

70.00

70.44% Upside

Current: 28.080

Low

36.00

Averages

47.86

High

70.00

BTIG

David Larsen

Buy

downgrade

$70 -> $50

2025-07-30

Reason

BTIG

David Larsen

Price Target

$70 -> $50

2025-07-30

downgrade

Buy

Reason

BTIG analyst David Larsen lowered the firm's price target on Astrana Health to $50 from $70 and keeps a Buy rating on the shares. The company could face headwinds from higher cost trends, though it has already provided favorable comments around Q2 results, the analyst tells investors in a research note. There have been some worries about home-health reimbursement, but the specialty medical trend and home-health and rehab volumes will likely far offset these worries, the firm added.

Barclays

Andrew Mok

Hold

Initiates

$36

2025-04-01

Reason

Barclays

Andrew Mok

Price Target

$36

2025-04-01

Initiates

Hold

Reason

Barclays initiated coverage of Astrana Health with an Equal Weight rating and $36 price target. The company is well positioned to capture improving rates in the government sector, but the scale and complexity of the pending Prospect deal tempers excitement, the analyst tells investors in a research note. The firm believes the near-term execution risks are real given the scale. As such, it comes out on the sidelines.

Truist Securities

Jailendra Singh

Strong Buy

Maintains

$50 → $46

2025-03-18

Reason

Truist Securities

Jailendra Singh

Price Target

$50 → $46

2025-03-18

Maintains

Strong Buy

Reason

Truist analyst Jailendra Singh lowered the firm's price target on Astrana Health to $46 from $50 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company's Q4 earnings release and 2025 outlook, the analyst tells investors in a research note. Truist adds that its valuation represents a slight premium to Astrana's next-12-months enterprise value to EBITDA average multiple over the last year and gives credit to its recent history of outperformance relative to the value-based care industry as a whole.

B of A Securities

Adam Ron

Strong Buy

Maintains

$55 → $49

2025-03-04

Reason

B of A Securities

Adam Ron

Price Target

$55 → $49

2025-03-04

Maintains

Strong Buy

Reason

Baird

Michael Ha

Buy

Maintains

$86 → $50

2025-03-03

Reason

Baird

Michael Ha

Price Target

$86 → $50

2025-03-03

Maintains

Buy

Reason

Baird lowered the firm's price target on Astrana Health to $50 from $86 and keeps an Outperform rating on the shares.

Stifel

Craig Jones

Strong Buy

Maintains

$70 → $56

2025-02-20

Reason

Stifel

Craig Jones

Price Target

$70 → $56

2025-02-20

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on Astrana Health to $56 from $70 and keeps a Buy rating on the shares ahead of Astrana reporting Q4 earnings on Thursday, February 27. The firm expects the call to be focused on integration of CHS and close of Prospect Health, 2025 guidance and medical cost trends, and progress in transitioning to full-risk, the analyst tells investors in a preview.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Astrana Health Inc (ASTH.O) is 13.70, compared to its 5-year average forward P/E of 36.86. For a more detailed relative valuation and DCF analysis to assess Astrana Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

36.86

Current PE

13.70

Overvalued PE

56.37

Undervalued PE

17.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

11.79

Current EV/EBITDA

3.47

Overvalued EV/EBITDA

18.02

Undervalued EV/EBITDA

5.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

1.38

Current PS

0.27

Overvalued PS

2.41

Undervalued PS

0.36

Financials

Annual

Quarterly

FY2025Q2

YoY :

+34.66%

654.81M

Total Revenue

FY2025Q2

YoY :

-32.35%

20.34M

Operating Profit

FY2025Q2

YoY :

-53.28%

10.22M

Net Income after Tax

FY2025Q2

YoY :

-52.50%

0.19

EPS - Diluted

FY2025Q2

YoY :

+339.66%

89.48M

Free Cash Flow

FY2025Q2

YoY :

-20.10%

10.85

Gross Profit Margin - %

FY2025Q2

YoY :

+61.09%

5.01

FCF Margin - %

FY2025Q2

YoY :

-65.33%

1.56

Net Margin - %

FY2025Q2

YoY :

-53.49%

4.66

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ASTH News & Events

Events Timeline

2025-08-07 (ET)

2025-08-07

16:49:57

Astrana Health sees 2025 revenue $3.1B-$3.3B, consensus $3.18B

2025-08-07

16:49:11

Astrana Health sees Q3 revenue $925M-$965M, consensus $943.74M

2025-08-07

16:48:22

Astrana Health reports Q2 EPS 19c vs. 40c last year

News

4.5

08-08Benzinga

S&P 500 Moves Higher; Under Armour Shares Tumble After Q1 Results

2.0

08-08Benzinga

SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday

6.5

07-11NASDAQ.COM

Zacks.com featured highlights Astrana Health, KT, Upbound, Noah Holdings and DXP Enterprises

People Also Watch

Vita Coco Company Inc

DigitalBridge Group Inc

Beam Therapeutics Inc

Hillman Solutions Corp

Transportadora de Gas del Sur SA

Lionsgate Studios Corp

FAQ

What is Astrana Health Inc (ASTH) stock price today?

The current price of ASTH is 28.08 USD — it has increased 30.85 % in the last trading day.

ASTH

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ASTH News & Events

Events Timeline

News

People Also Watch

FAQ

What is Astrana Health Inc (ASTH) stock price today?

What is Astrana Health Inc (ASTH)'s business?

What is the price predicton of ASTH Stock?

What is Astrana Health Inc (ASTH)'s revenue for the last quarter?

What is Astrana Health Inc (ASTH)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Astrana Health Inc (ASTH)'s fundamentals?

How many employees does Astrana Health Inc (ASTH). have?

What is Astrana Health Inc (ASTH) market cap?